Phase 2 N=20 Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis
Wegener's Granulomatosis
Primary: Safety of Abatacept - Number of Participants With Adverse Events — 7; 16; 14; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=197 Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
Vasculitis · Wegener's Granulomatosis · Microscopic Polyangiitis
Primary: Disease Remission — 63; 52 Participants — p=<0.001
Phase 2 N=45 Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis
Wegener's Granulomatosis
Primary: Remission of Vasculitis — 95 Percentage of participants
Phase 3 N=105 Belimumab in Remission of VASculitis
Vasculitis
Primary: Time to First Relapse — NA; NA Days — p=0.884
Phase 2 N=25 A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
Granulomatosis With Polyangiitis
Primary: Percentage of Participants With Adverse Events (AEs), Including Serious AEs — 100; 100; 28; 48 percentage of participants
N/A N=97 An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
Granulomatosis With Polyangiitis · Microscopic Polyangiitis
Primary: Incidence Rate of Serious Infections — 7.11 events per 100 patient year
N/A N=80 Anti-neutrophil Cytoplasmic Antibody in Interstitial Lung Disease.
Interstitial Lung Disease · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Primary: Death From All Causes — 10; 5 Participants
N/A N=118 Mepolizumab Long-term Study to Assess Real World Safety and Effectiveness of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Japan
Churg-Strauss Syndrome · Eosinophilic Granulomatosis With Polyangiitis
Primary: Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interests (AESI) — 69; 26; 42 Participants
Phase 2 N=57 Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
Granulomatosis With Polyangiitis (GPA) · Microscopic Polyangiitis (MPA)
Primary: Percentage of Subjects Achieving Clinical Response — 16; 22; 10 Participants
Phase 3 N=136 A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis
Churg-Strauss Syndrome
Primary: Number of Participants in Each Category of Accrued Duration of Remission — 55; 32; 8; 8 Participants — p=<0.001
Phase 4 N=20 Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
Granulomatosis With Polyangiitis · Microscopic Polyangiitis
Primary: Complete Remission — 14 Participants
Phase 3 N=704 Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis
Granulomatosis With Polyangiitis (Wegener's) (GPA) · Microscopic Polyangiitis (MPA)
Primary: Composite of i) All-cause Mortality or ii) End-stage Renal Disease — 100; 109 Participants
N/A N=120 Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma
Churg-Strauss Syndrome · Eosinophilic Asthma · Eosinophilic Esophagitis
Primary: Number and Percentage of Patients With a Positive Autoantibody ELISA — 19; 4; 3; 4 Participants
Phase 3 N=331 A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
ANCA-Associated Vasculitis
Primary: Percentage of Subjects Achieving Disease Remission at Week 26 — 70.1; 72.3 percentage of participants — p=< 0.0001
Phase 2 N=42 Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis
ANCA-associated Vasculitis
Primary: Incidence of Adverse Events — 13; 11; 15 Participants
Phase 2 N=94 Treatment and Natural History Study of Lymphomatoid Granulomatosis
Lymphomatoid Granulomatosis · Granulomatosis, Lymphomatoid · Non-Hodgkins Lymphoma
Primary: Overall Response Rate (ORR) — 53.45; 51.85; 57.14; 50.00 percentage of participants
Phase 2 N=67 A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis
Vasculitis
Primary: Proportion of Subjects Achieving Disease Response at Day 85 — 0.7; 0.86; 0.81 proportion of participants
Phase 2 N=18 Inhaled GM-CSF Therapy of Autoimmune PAP
Autoimmune Pulmonary Alveolar Proteinosis
Primary: Time to Rescue WLL — 18; 30 Months — p=0.0078
Phase 2 N=30 Tocilizumab for Patients With Giant Cell Arteritis
Giant Cell Arteritis
Primary: Number of Patients That Have Achieved Complete Remission of Disease — 17; 4 Participants — p=0.0301
Phase 3 N=170 Rituximab Vasculitis Maintenance Study
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Microscopic Polyangiitis · Wegener Granulomatosis
Primary: Relapse-free Survival — 38; 60; 13; 32 participants
N/A N=165 Validation of a Diagnostic Algorithm of Giant Cell Arteritis
Giant Cell Arteritis
Primary: Number of CDU False-positive Patients — 73; 63; 0; 29 Participants
Phase 2 N=19 Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma
SYSTEMIC SCLERODERMA
Primary: Time to Treatment Failure — 0; 8 participants
Phase 2 N=83 Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis
Takayasu's Arteritis · Giant Cell Arteritis
Primary: Primary Outcome - Relapse-free Survival (RFS) — 10; 14; 8; 10 Participants — p=0.049
Phase 3 N=100 Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921
Churg-Strauss Syndrome · Eosinophilic Granulomatosis With Polyangiitis
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 98; 38 Participants
Phase 2 N=10 Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome
Churg Strauss Syndrome
Primary: Number of Participants With Indicated Side Effects — 3; 1; 0; 1 Participants
Phase 2 N=57 Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Systemic Sclerosis-Associated PAH
Primary: Change From Baseline in Distance Walked During a Six Minute Walk Test — 23.6; 0.5 Meters — p=0.12
Phase 3 N=158 Scleroderma Lung Disease
Lung Diseases · Pulmonary Fibrosis · Systemic Scleroderma
Primary: Forced Vital Capacity — 66.6; 65.6 % of predicted
Phase 4 N=34 Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy
IgA Nephropathy
Primary: Change in Proteinuria at 12 Months — 3; 3; 1; 2 participants
Phase 2 N=2 Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)
Hereditary Pulmonary Alveolar Proteinosis
Primary: Change in Time (Minutes) to Discontinuation of Exercise During a Standardized Treadmill Exercise Test — 17; 33 Percent Change
Phase 4 N=30 Tocilizumab Plus a Short Prednisone Taper for GCA
Giant Cell Arteritis
Primary: Sustained Remission — 23 Participants